{"id":464216,"date":"2021-03-24T09:03:24","date_gmt":"2021-03-24T13:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=464216"},"modified":"2021-03-24T09:03:24","modified_gmt":"2021-03-24T13:03:24","slug":"kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/","title":{"rendered":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PHILADELPHIA, March  24, 2021  (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (\u201cAcadia\u201d or the \u201cCompany\u201d) (NASDAQ: ACAD) on behalf of the Company\u2019s stockholders. The investigation seeks to determine whether the members of Acadia\u2019s board of directors breached their fiduciary duties to the Company and its stockholders.\u00a0\u00a0<\/p>\n<p align=\"justify\">Current Acadia stockholders who purchased or acquired shares of the Company\u2019s stock <strong><em><u>prior to April 9, 2018<\/u><\/em><\/strong> are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 \u2013 1585, or by email at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jri1FG0SfGUYKgnXKc9BgMSD6qVkeT83Y8aIlJABbzVYd3sxWdY_YNlXrQQmxLqeUfJWy6mNFFaC30fPS4L7Om_iTb9x7aTfF7hbtZ18rGE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">skaskela@kaskelalaw.com<\/a> or online at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HH9Gkf33NUTP80qzBqE5avjDGZm2vocxw3RBCDKloZBB0SsQIimPm3fkC4Y_eYbQpdmjRBCLHjDbLngqbZzX5yiSJ9SbFtUAhjtu9oe6hE3HzbMeeaW3Fzqw4zRge9fFGTrh4xKufspdsn9hl9xOLyj221nk8b3xA5LLTvEgFI6y_h0KQ30X4DHBxKLAkymy\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><em>https:\/\/kaskelalaw.com\/case\/acadia-pharmaceuticals-inc\/<\/em><\/strong><\/a>, for additional information about this investigation and their legal rights and options with respect to this matter.<\/p>\n<p align=\"justify\">Recently a securities fraud complaint was filed against Acadia and certain of the Company\u2019s executive officers on behalf of investors who purchased shares of Acadia\u2019s stock between April 29, 2016 and July 9, 2018. According to the complaint, during that time period the defendants made a series of materially false and\/or misleading statements, and failed to disclose material adverse facts to investors, including that: (i) adverse events, safety concerns, and mounting reports of deaths related to NUPLAZID post-commercialization raised the risk that the FDA would reconsider its approval of the drug or, at minimum, that industry watchdogs would warn against prescribing the drug; (ii) as a result of NUPLAZID\u2019s deleterious safety profile and the availability of off-label alternatives, Acadia embarked on a campaign to pay off physicians to prescribe NUPLAZID; and (iii) these improper business practices, in contravention of federal regulations, raised a risk that Acadia would face regulatory scrutiny.<\/p>\n<p align=\"justify\">On April 9, 2018, CNN reported that \u201c[p]hysicians, medical researchers and other experts told CNN that they worried that [NUPLAZID] had been approved too quickly, based on too little evidence that it was safe or effective. And given these mounting reports of deaths, they say that more needs to be done to assess Nuplazid\u2019s true risks.\u201d\u00a0\u00a0 <strong><em>On this news, Acadia\u2019s stock price fell $5.03 per share, or over 23% in value.<\/em><\/strong><\/p>\n<p align=\"justify\">On April 25, 2018, CNN reported that the FDA was re-examining the safety of NUPLAZID. <strong><em>On this news, Acadia\u2019s stock price fell $4.27 per share, or 22% in value.<\/em><\/strong><\/p>\n<p align=\"justify\">Finally, on July 9, 2018, the Southern Investigative Reporting Foundation (\u201cSIRF\u201d) published a report critical of Acadia and NUPLAZID. <strong><em>On this news, Acadia\u2019s stock price fell nearly 7% in value.<\/em><\/strong><\/p>\n<p align=\"justify\">Current Acadia stockholders who purchased or acquired shares of the Company\u2019s stock <strong><em><u>prior to April 9, 2018 <\/u><\/em><\/strong>are encouraged to contact Kaskela Law LLC for additional information about this investigation and their legal rights and options with respect to this matter.<\/p>\n<p align=\"justify\">Kaskela Law LLC represents investors in securities fraud, corporate governance, and merger &amp; acquisition litigation. For additional information about Kaskela Law LLC please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5ayiLvEUfgQzEXs4g9EBByEDKQUodvS5AbS-i6y67jmBQDSFvccuzORlkeG3nD1mi5Hbj24n5zUDqaw226OHCvEyOp3ioQ6Z4uHn5TaIco=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kaskelalaw.com<\/a>. This notice may constitute attorney advertising in certain jurisdictions.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p align=\"justify\">D. Seamus Kaskela, Esq.<br \/><strong>KASKELA LAW LLC<\/strong><br \/>18 Campus Blvd., Suite 100<br \/>Newtown Square, PA 19073<br \/>(484) 258 \u2013 1585<br \/>(888) 715 \u2013 1740<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=V5ayiLvEUfgQzEXs4g9EBGwurgjdAVLW3NXya05nS78SBFOqFcaoHzLNFVoiiMOfscQZJNZ3rPTJy9F0Xo6NhGEug8byJmyz286cWzb48ws=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.kaskelalaw.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jri1FG0SfGUYKgnXKc9BgMSD6qVkeT83Y8aIlJABbzU8_hG6iOOClQfjx3xXop-qllCJDzbqCpObv4qRNBlDzGVWqX5-14CzQjPJUoEy4lc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">skaskela@kaskelalaw.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9d0f2c0e-419a-4864-9818-bc2e493daeea\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (\u201cAcadia\u201d or the \u201cCompany\u201d) (NASDAQ: ACAD) on behalf of the Company\u2019s stockholders. The investigation seeks to determine whether the members of Acadia\u2019s board of directors breached their fiduciary duties to the Company and its stockholders.\u00a0\u00a0 Current Acadia stockholders who purchased or acquired shares of the Company\u2019s stock prior to April 9, 2018 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 \u2013 1585, or by email at skaskela@kaskelalaw.com or online at https:\/\/kaskelalaw.com\/case\/acadia-pharmaceuticals-inc\/, for additional information about this investigation and their legal rights and options with respect to this matter. Recently a securities fraud complaint was filed against &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-464216","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (\u201cAcadia\u201d or the \u201cCompany\u201d) (NASDAQ: ACAD) on behalf of the Company\u2019s stockholders. The investigation seeks to determine whether the members of Acadia\u2019s board of directors breached their fiduciary duties to the Company and its stockholders.\u00a0\u00a0 Current Acadia stockholders who purchased or acquired shares of the Company\u2019s stock prior to April 9, 2018 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 \u2013 1585, or by email at skaskela@kaskelalaw.com or online at https:\/\/kaskelalaw.com\/case\/acadia-pharmaceuticals-inc\/, for additional information about this investigation and their legal rights and options with respect to this matter. Recently a securities fraud complaint was filed against &hellip; Continue reading &quot;Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-24T13:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm\",\"datePublished\":\"2021-03-24T13:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/\"},\"wordCount\":502,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/\",\"name\":\"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\",\"datePublished\":\"2021-03-24T13:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk","og_description":"PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) &#8212; Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. (\u201cAcadia\u201d or the \u201cCompany\u201d) (NASDAQ: ACAD) on behalf of the Company\u2019s stockholders. The investigation seeks to determine whether the members of Acadia\u2019s board of directors breached their fiduciary duties to the Company and its stockholders.\u00a0\u00a0 Current Acadia stockholders who purchased or acquired shares of the Company\u2019s stock prior to April 9, 2018 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 \u2013 1585, or by email at skaskela@kaskelalaw.com or online at https:\/\/kaskelalaw.com\/case\/acadia-pharmaceuticals-inc\/, for additional information about this investigation and their legal rights and options with respect to this matter. Recently a securities fraud complaint was filed against &hellip; Continue reading \"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-24T13:03:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm","datePublished":"2021-03-24T13:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/"},"wordCount":502,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/","name":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=","datePublished":"2021-03-24T13:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwNTMwMSM0MDg4NjU2IzIwOTk5MzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kaskela-law-llc-announces-investigation-of-acadia-pharmaceuticals-inc-acad-and-encourages-long-term-acad-stockholders-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kaskela Law LLC Announces Investigation of Acadia Pharmaceuticals Inc. (ACAD) and Encourages Long-Term ACAD Stockholders to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=464216"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/464216\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=464216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=464216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=464216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}